3 results match your criteria: "Nepal (Dr. Pandey); and Kathmandu University School of Medical Sciences[Affiliation]"
Background: Drug is a double-edged sword. Though important, Adverse Drug Reactions under-reporting is real and is mainly due to lack of awareness. No published research has ever evaluated the perspective of third year medical students towards Adverse Drug Reactions reporting.
View Article and Find Full Text PDFEffects of Momordica Charantia (Karela/bitterguord) in Type 2 Diabetic Patients Taking Allopathic Drugs: A pilot study.
Kathmandu Univ Med J (KUMJ)
November 2021
Department of Clinical Pharmacology, B P Koirala Institute of Health Sciences, Dharan, Nepal.
Background Momordica charantia is evoloving as supplementary therapy in type 2 diabetes mellitus. Animal studies reveal its anti-diabetic and lipid lowering property. However, clinical studies with human subjects are very few.
View Article and Find Full Text PDFCatastrophic health expenditure among industrial workers in a large-scale industry in Nepal, 2017: a cross-sectional study.
BMJ Open
November 2018
School of Public Health and Community Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
Objectives: The study aimed at estimating out-of-pocket (OOP) expenditure, catastrophic health expenditure (CHE) and distress financing due to hospitalisation and outpatient care among industrial workers in Eastern Nepal.
Methods: We conducted a cross-sectional study involving industrial workers employed in a large-scale industry in Eastern Nepal. Those who were hospitalised in the last 1 year or availed outpatient care within the last 30 days were administered a structured questionnaire to estimate the cost of illness.